🇺🇸 FDA
Patent

US 7662815

Diaryl ether β2 adrenergic receptor agonists

granted A61PA61P11/00A61P11/06

Quick answer

US patent 7662815 (Diaryl ether β2 adrenergic receptor agonists) held by Theravance, Inc. expires Mon Feb 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Feb 16 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P11/00, A61P11/06, A61P15/06, A61P25/00